Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.35 |
| ▸ | KDM6B | O15054 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4061073 | 0.86 | HCAR2 (0.46) | HCAR2POLBKDM4EKMT2AAKR1C3 | |
| SCHEMBL29954221 | 0.86 | HCAR2 (0.37) | HCAR2POLBKDM4EKMT2AAKR1C3 | |
| SCHEMBL1171212 | 0.84 | KDM4E (0.47) | HCAR2POLBKDM4EKMT2AAKR1C3 | |
| SCHEMBL28811169 | 0.81 | ATM (0.42) | POLBKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL29860483 | 0.81 | ATM (0.42) | POLBKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL659061 | 0.80 | HCAR2 (0.42) | HCAR2POLBKDM4EKMT2AAKR1C3 | |
| SCHEMBL15334246 | 0.78 | AKR1C3 (0.50) | HCAR2POLBKDM4EKMT2AAKR1C3 | |
| Nitrous Acid SCHEMBL28696829 | 0.78 | HCAR2 (0.41) | HCAR2POLBKDM4EKMT2AALDH1A1 | |
| SCHEMBL16694995 | 0.77 | HCAR2 (0.39) | HCAR2POLBKDM4EKMT2AAKR1C3 | |
| SCHEMBL21825962 | 0.77 | HDAC3 (0.41) | HCAR2POLBKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11628161-B2 | Isoindoline derivative, pharmaceutical composition and use thereof | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2023-04-18 | — | — | US | disclosed |
| CN-110291065-B | Novel isoindoline derivative, pharmaceutical composition and application thereof | 康朴生物医药技术（上海）有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-11337964-B2 | Isoindoline derivative, pharmaceutical composition and use thereof | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2022-05-24 | — | — | US | disclosed |
| US-20220152002-A1 | ISOINDOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2022-05-19 | — | — | US | disclosed |
| EP-3590924-B1 | NOVEL ISOINDOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2021-10-27 | — | — | EP | disclosed |
| EP-3590924-B1 | NOVEL ISOINDOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2021-10-27 | — | — | EP | disclosed |
| US-20200061033-A1 | NOVEL ISOINDOLINE DERIVATIVE, A PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2020-02-27 | — | — | US | disclosed |
| CN-103788070-B | The inhibitor class polymers of DPP 4 | 南京华威医药科技开发有限公司 | 2017-10-20 | — | — | CN | disclosed |
| CN-103788070-A | DPP-4 inhibitor polymer | NANJING HUAWE MEDICAL TECHNOLOGY DEV CO LTD | 2014-05-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11337964-B2 | Isoindoline derivative, pharmaceutical composition and use thereof | PDE4A, PDE4B, PDE4C | HCAR2 990/4885POLB 1556/4885KDM4E 2116/4885 |
| US-20200061033-A1 | NOVEL ISOINDOLINE DERIVATIVE, A PHARMACEUTICAL COMPOSITION AND USE THEREOF | PDE4A, PDE4B, PDE4C | HCAR2 1302/4885POLB 1689/4885KDM4E 1972/4885 |
| US-11628161-B2 | Isoindoline derivative, pharmaceutical composition and use thereof | PDE4A, PDE4B, PDE4C | HCAR2 990/4885POLB 1556/4885KDM4E 2116/4885 |
| US-20220152002-A1 | ISOINDOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | PDE4A, PDE4B, PDE4C | HCAR2 999/4885POLB 1611/4885KDM4E 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.